ELI LILLY AND COMPANY Payments to Acquire Long-term Investments
ELI LILLY AND COMPANY (LLY) reported Payments to Acquire Long-term Investments of $474.10 million for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-01.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireLongtermInvestments · last filed 2022-11-01
- ELI LILLY AND COMPANY payments to acquire long-term investments for the quarter ending 2022-09-30 was $222.70M, a 7.58% increase year-over-year.
- ELI LILLY AND COMPANY payments to acquire long-term investments for the quarter ending 2022-06-30 was $134.70M, a 36.34% decline year-over-year.
- ELI LILLY AND COMPANY payments to acquire long-term investments for the quarter ending 2022-03-31 was $116.70M, a 59.97% decline year-over-year.
- ELI LILLY AND COMPANY payments to acquire long-term investments for the quarter ending 2021-09-30 was $207.00M, a 200.44% increase year-over-year.
| Period end | Payments to Acquire Long-term Investments 3 month | Payments to Acquire Long-term Investments 6 month | Payments to Acquire Long-term Investments 9 month |
|---|---|---|---|
| 2022-09-30 | $222.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | $357.40M derived: sum of 2 quarters · filed 2022-11-01 | $474.10M 10-Q · filed 2022-11-01 |
| 2022-06-30 | $134.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $251.40M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $116.70M 10-Q · filed 2022-04-29 | ||
| 2021-09-30 | $207.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | $418.60M derived: sum of 2 quarters · filed 2022-11-01 | $710.10M 10-Q · filed 2022-11-01 |
| 2021-06-30 | $211.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $503.10M 10-Q · filed 2022-08-04 | |
| 2021-03-31 | $291.50M 10-Q · filed 2022-04-29 | ||
| 2020-09-30 | $68.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-27 | $140.70M derived: sum of 2 quarters · filed 2021-10-27 | $223.70M 10-Q · filed 2021-10-27 |
| 2020-06-30 | $71.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | $154.80M 10-Q · filed 2021-08-03 | |
| 2020-03-31 | $83.00M 10-Q · filed 2021-04-30 | ||
| 2019-09-30 | $50.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-28 | $136.10M derived: sum of 2 quarters · filed 2020-10-28 | $196.70M 10-Q · filed 2020-10-28 |
| 2019-06-30 | $86.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-31 | $146.60M 10-Q · filed 2020-07-31 | |
| 2019-03-31 | $60.60M 10-Q · filed 2020-05-01 | ||
| 2018-09-30 | $43.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-25 | $158.10M derived: sum of 2 quarters · filed 2019-10-25 | $719.70M 10-Q · filed 2019-10-25 |
| 2018-06-30 | $114.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-02 | $676.50M 10-Q · filed 2019-08-02 | |
| 2018-03-31 | $561.60M 10-Q · filed 2019-05-02 | ||
| 2017-09-30 | $1.38B derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $2.79B derived: sum of 2 quarters · filed 2018-11-06 | $3.74B 10-Q · filed 2018-11-06 |
| 2017-06-30 | $1.41B derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-25 | $2.36B 10-Q · filed 2018-07-25 | |
| 2017-03-31 | $945.90M 10-Q · filed 2018-04-27 | ||
| 2016-09-30 | $1.37B derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-27 | $2.92B derived: sum of 2 quarters · filed 2017-10-27 | $3.64B 10-Q · filed 2017-10-27 |
| 2016-06-30 | $1.55B derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-28 | $2.27B 10-Q · filed 2017-07-28 | |
| 2016-03-31 | $716.70M 10-Q · filed 2017-05-01 | ||
| 2015-09-30 | $840.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-28 | $1.75B derived: sum of 2 quarters · filed 2016-10-28 | $2.67B 10-Q · filed 2016-10-28 |
| 2015-06-30 | $908.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-07-28 | $1.83B 10-Q · filed 2016-07-28 | |
| 2015-03-31 | $924.40M 10-Q · filed 2016-04-29 | ||
| 2014-09-30 | $3.04B derived: 10-Q 9 month − 10-Q 6 month · filed 2015-10-30 | $5.87B derived: sum of 2 quarters · filed 2015-10-30 | $8.64B 10-Q · filed 2015-10-30 |
| 2014-06-30 | $2.82B derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-30 | $5.59B 10-Q · filed 2015-07-30 | |
| 2014-03-31 | $2.77B 10-Q · filed 2015-04-30 | ||
| 2013-09-30 | $3.76B derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-29 | $8.38B derived: sum of 2 quarters · filed 2014-10-29 | $10.24B 10-Q · filed 2014-10-29 |
| 2013-06-30 | $4.61B derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-28 | $6.48B 10-Q · filed 2014-07-28 | |
| 2013-03-31 | $1.86B 10-Q · filed 2014-04-28 | ||
| 2012-09-30 | $5.51B 10-Q · filed 2013-10-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |